Context Therapeutics (CNTX) Gains from Investment Securities (2021 - 2026)

Context Therapeutics has disclosed Gains from Investment Securities across 5 years of filings, most recently posting $201058.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $201058.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $201058.0 (down 22.86% YoY), and the FY2024 annual result was $260638.0, changed N/A from the prior year.
• Gains from Investment Securities came in at $201058.0 for Q1 2026 at Context Therapeutics, down from $260638.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $260638.0 in Q3 2024 to a low of -$6562.0 in Q1 2023.
• The 4-year median for Gains from Investment Securities is $69619.0 (2022), against an average of $98697.3.
• Across the five-year window, Gains from Investment Securities tumbled 105.03% in 2023 and surged 2878.72% in 2024, its largest moves.
• Context Therapeutics' Gains from Investment Securities stood at $130488.0 in 2022, then plunged by 93.29% to $8750.0 in 2023, then soared by 2878.72% to $260638.0 in 2024, then fell by 22.86% to $201058.0 in 2026.
• The last three Gains from Investment Securities figures came in at $201058.0 (Q1 2026), $260638.0 (Q3 2024), and $8750.0 (Q3 2023), per Business Quant data.